Lycopene inhibits ER stress and apoptosis while modulating PI3K/AKT and enhancing antioxidant and anti-apoptotic proteins
Authors:
Open Access
- 23 December 2025
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 20 (12) , e0339565
Abstract
Acute kidney injury (AKI) is a critical clinical syndrome with limited therapeutic options. This study investigated the renoprotective effects of lycopene, a potent antioxidant, in both in vivo and in vitro AKI models. In a murine cecal ligation and puncture (CLP)-induced sepsis-AKI model, pretreatment with lycopene (10, 20, 40 mg/kg) dose-dependently ameliorated renal histopathological damage (HE staining) and restored serum biomarkers (AST, ALT, BUN, CREA). Mechanistically, lycopene suppressed oxidative stress and apoptosis by downregulating the PI3K/Akt axis: it significantly reversed the CLP-induced upregulating of p-PI3K and p-Akt, and the pro-apoptotic proteins (Bax, Cleaved Caspase-3), while increasing Nrf 2 and SOD1. Consistent results were observed in LPS- and H₂O₂-induced cellular AKI models, where lycopene attenuated cell death and restored redox homeostasis in a dose-dependent manner. Immunofluorescence assays further validated these trends. Crucially, PI3K siRNA or cDNA transfection experiments confirmed that lycopene’s antioxidant and anti-apoptotic effects were PI3K-dependent. Our findings highlight lycopene as a promising therapeutic agent for AKI, acting via PI3K/Akt-mediated activation of Nrf 2 to counteract oxidative damage and apoptosis. This study provides novel insights into the molecular mechanisms underlying lycopene’s renoprotection and supports its potential clinical translation for sepsis or oxidative stress-associated AKI.Keywords
Funding Information
- Zhejiang Provincial Education Department (Y202353817)
This publication has 48 references indexed in Scilit:
- Comparative Efficacy and Safety of Antibiotic Regimens in Sepsis-Induced Acute Kidney Injury: A Retrospective Cohort StudyClinical Therapeutics, 2025
- Targeting EGFR and PI3K/mTOR pathways in glioblastoma: innovative therapeutic approachesMedical Oncology, 2025
- Enhancing therapeutic efficacy: In vivo mechanisms and biochemical effects of lycopene encapsulated in nanomicelles for acute inflammation and lipid metabolismEuropean Journal of Pharmaceutics and Biopharmaceutics, 2024
- Micheliolide ameliorates lipopolysaccharide-induced acute kidney injury through suppression of NLRP3 activation by promoting mitophagy via Nrf2/PINK1/Parkin axisInternational Immunopharmacology, 2024
- The role of PI3K/Akt signaling pathway in chronic kidney diseaseInternational Urology and Nephrology, 2024
- Natural products targeting macroautophagy signaling in hepatocellular carcinoma therapy: Recent evidence and perspectivesPhytotherapy Research, 2024
- The role of PI3K/AKT signaling pathway in myocardial ischemia-reperfusion injuryInternational Immunopharmacology, 2023
- The Temporal and Spatial Changes of Autophagy and PI3K Isoforms in Different Neural Cells After Hypoxia/Reoxygenation InjuryMolecular Neurobiology, 2023
- Co-delivery of siRNA and lycopene encapsulated hybrid lipid nanoparticles for dual silencing of insulin-like growth factor 1 receptor in MCF-7 breast cancer cell lineInternational Journal of Biological Macromolecules, 2022
- The Lyt phenotype of the T cells in an antitumor adoptive transfer differs for “parent to F1” and “parent to parent” combinationsCellular Immunology, 1984